Immunogenicity and safety of COVID-19 vaccines in patients with pancreatic cancer

IF 2.7 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Hpb Pub Date : 2025-05-01 DOI:10.1016/j.hpb.2025.02.002

Leonoor V. Wismans , Rory D. de Vries , Casper W.F. van Eijck , Maaike Verheij , Susanne Bogers , Joachim G.J.V. Aerts , Corine H. GeurtsvanKessel , Casper H.J. van Eijck , Annemiek A. van der Eijk

{"title":"Immunogenicity and safety of COVID-19 vaccines in patients with pancreatic cancer","authors":"Leonoor V. Wismans , Rory D. de Vries , Casper W.F. van Eijck , Maaike Verheij , Susanne Bogers , Joachim G.J.V. Aerts , Corine H. GeurtsvanKessel , Casper H.J. van Eijck , Annemiek A. van der Eijk","doi":"10.1016/j.hpb.2025.02.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Patients with pancreatic ductal adenocarcinoma (PDAC) are at increased risk for severe COVID-19. Although COVID-19 vaccines are highly recommended for this population, studies on immunogenicity are lacking. We aimed to investigate the immunogenicity of COVID-19 vaccines in PDAC patients, compared to controls.</div></div><div><h3>Methods</h3><div>This observational study evaluated SARS-CoV-2 spike-specific IgG (S-IgG) levels after priming and booster vaccination in PDAC patients. Primary outcomes were seroprevalence and S-IgG levels compared to matched controls. Secondary outcomes included safety and the association of S-IgG levels with clinical and therapeutic characteristics.</div></div><div><h3>Results</h3><div>In 81 PDAC patients, a total of 86 matched S-IgG levels were available (33 post-priming; 53 post-booster). After priming, 88% (29/33) of PDAC patients were seropositive compared to 97% (32/33) of controls (<em>P</em>=0.16). After booster, seropositivity increased to 98% (52/53) in PDAC patients and to 53/53 (100%) in controls (<em>P</em>=0.31). Patients with active disease during booster vaccination had significantly lower S-IgG levels compared to patients with a history of PDAC (<em>P</em>=0.002). Cancer therapies were not associated with distinct S-IgG levels (<em>P</em>>0.05). No serious adverse events occurred.</div></div><div><h3>Conclusion</h3><div>Priming and booster COVID-19 vaccines are safe and immunogenic in PDAC patients, comparable to controls. The antibody response was effectively increased by the booster vaccination and not impaired by cancer therapies.</div></div>","PeriodicalId":13229,"journal":{"name":"Hpb","volume":"27 5","pages":"Pages 716-722"},"PeriodicalIF":2.7000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hpb","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1365182X25000619","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Patients with pancreatic ductal adenocarcinoma (PDAC) are at increased risk for severe COVID-19. Although COVID-19 vaccines are highly recommended for this population, studies on immunogenicity are lacking. We aimed to investigate the immunogenicity of COVID-19 vaccines in PDAC patients, compared to controls.

Methods

This observational study evaluated SARS-CoV-2 spike-specific IgG (S-IgG) levels after priming and booster vaccination in PDAC patients. Primary outcomes were seroprevalence and S-IgG levels compared to matched controls. Secondary outcomes included safety and the association of S-IgG levels with clinical and therapeutic characteristics.

Results

In 81 PDAC patients, a total of 86 matched S-IgG levels were available (33 post-priming; 53 post-booster). After priming, 88% (29/33) of PDAC patients were seropositive compared to 97% (32/33) of controls (P=0.16). After booster, seropositivity increased to 98% (52/53) in PDAC patients and to 53/53 (100%) in controls (P=0.31). Patients with active disease during booster vaccination had significantly lower S-IgG levels compared to patients with a history of PDAC (P=0.002). Cancer therapies were not associated with distinct S-IgG levels (P>0.05). No serious adverse events occurred.

Conclusion

Priming and booster COVID-19 vaccines are safe and immunogenic in PDAC patients, comparable to controls. The antibody response was effectively increased by the booster vaccination and not impaired by cancer therapies.

Abstract Image

查看原文本刊更多论文

COVID-19疫苗在胰腺癌患者中的免疫原性和安全性

背景：胰腺导管腺癌（PDAC）患者发生严重COVID-19的风险增加。尽管对这一人群强烈推荐COVID-19疫苗，但缺乏免疫原性研究。我们的目的是研究COVID-19疫苗在PDAC患者中的免疫原性，与对照组相比。方法：本观察性研究评估了PDAC患者启动和加强接种后SARS-CoV-2刺特异性IgG （S-IgG）水平。主要结果是与匹配对照组相比的血清阳性率和S-IgG水平。次要结果包括安全性和S-IgG水平与临床和治疗特征的关系。结果：在81例PDAC患者中，共有86个匹配的S-IgG水平可用(33个启动后；53 post-booster)。启动后，88%（29/33）的PDAC患者血清阳性，而对照组为97% (32/33)（P=0.16）。经强化后，PDAC患者血清阳性率上升至98%(52/53)，对照组血清阳性率上升至53/53 (100%)（P=0.31）。与有PDAC病史的患者相比，加强疫苗接种期间活动性疾病患者的S-IgG水平显著降低（P=0.002）。肿瘤治疗与S-IgG水平无明显相关性（P < 0.05）。未发生严重不良事件。结论：PDAC患者启动和加强的COVID-19疫苗是安全的，具有免疫原性，与对照组相当。抗体反应有效地增加了加强疫苗接种和不损害癌症治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hpb GASTROENTEROLOGY & HEPATOLOGY-SURGERY

CiteScore

5.60

自引率

3.40%

发文量

244

审稿时长

57 days

期刊介绍： HPB is an international forum for clinical, scientific and educational communication. Twelve issues a year bring the reader leading articles, expert reviews, original articles, images, editorials, and reader correspondence encompassing all aspects of benign and malignant hepatobiliary disease and its management. HPB features relevant aspects of clinical and translational research and practice. Specific areas of interest include HPB diseases encountered globally by clinical practitioners in this specialist field of gastrointestinal surgery. The journal addresses the challenges faced in the management of cancer involving the liver, biliary system and pancreas. While surgical oncology represents a large part of HPB practice, submission of manuscripts relating to liver and pancreas transplantation, the treatment of benign conditions such as acute and chronic pancreatitis, and those relating to hepatobiliary infection and inflammation are also welcomed. There will be a focus on developing a multidisciplinary approach to diagnosis and treatment with endoscopic and laparoscopic approaches, radiological interventions and surgical techniques being strongly represented. HPB welcomes submission of manuscripts in all these areas and in scientific focused research that has clear clinical relevance to HPB surgical practice. HPB aims to help its readers - surgeons, physicians, radiologists and basic scientists - to develop their knowledge and practice. HPB will be of interest to specialists involved in the management of hepatobiliary and pancreatic disease however will also inform those working in related fields. Abstracted and Indexed in: MEDLINE® EMBASE PubMed Science Citation Index Expanded Academic Search (EBSCO) HPB is owned by the International Hepato-Pancreato-Biliary Association (IHPBA) and is also the official Journal of the American Hepato-Pancreato-Biliary Association (AHPBA), the Asian-Pacific Hepato Pancreatic Biliary Association (A-PHPBA) and the European-African Hepato-Pancreatic Biliary Association (E-AHPBA).